SavedAdd your journal

Journals / Retina-Vitreus / 2015 / Cilt: 23 - Sayı: 2

Retinopathy of Prematurity, Diagnosis and Standardization of the Evaluation

Prematüre Retinopatisi, Tanısı ve Değerlendirmede Standardizasyon

MEHMET ERHAN YUMUŞAK
Fatih Mehmet MUTLU
Ümit SARICA
Reyhan OĞUREL
Pages
179–185
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article it was aimed to review the up-to-date studies about the diagnosis and treatment of ROP and plus disease

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Retinopathy of prematurity (ROP) has been one of the issues about which the specialists have most argued but not compromised to that extent since its first definition.
📊
Key Findings & Data:Plus disease, defined in 1980 has been used as an important indicator in the diagnosis and treatment of ROP.
💡
Conclusion & Impact:In this article it was aimed to review the up-to-date studies about the diagnosis and treatment of ROP and plus disease
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Retinopathy of prematurity (ROP) has been one of the issues about which the specialists have most argued but not compromised to that extent since its first definition. Restricted examination area of the eyes of the premature babies and difficulty of performing examination, and difficulty in achieving sufficient pupil dilatation have precluded the standardization of diagnosis and treatment. Plus disease, defined in 1980 has been used as an important indicator in the diagnosis and treatment of ROP. With a later revision, concepts such as preplus or threshold have been defined, and changes in posterior pole have gained much more importance. Desire of the ROP specialists in using technology towards the diagnosis of plus disease and consensus about the diagnosis has significantly increased in the last 10 years. In this article it was aimed to review the up-to-date studies about the diagnosis and treatment of ROP and plus disease

Özet

Prematüre retinopatisi (PR), ilk tanımlanmasından sonra uzmanların üzerinde en çok tartıştıkları, tedavi seçeneklerinin gelişmesine rağmen özellikle tarama kriterleri ve tedavi endikasyonunun belirlemesinde muayene bulgularının standardizasyonu konusunda tam mutabakat sağlanamamıştır. Prematüre bebeklerin gözlerinin muayene zorlukları ve medikolegal sorunlar, tanı ve tedavinin standardizasyonun önüne geçmiştir. Plus hastalığı, hastalığın tanı ve tedavisinde önemli bir gösterge olarak kullanılmıştır. Son yıllarda sınıflamada yapılan revizyonlarla "eşik-PR", "eşik öncesi PR" ve "plus öncesi", gibi kavramlar gündeme gelmiş ve arka kutuptaki değişiklikler önem kazanmıştır. PR ile uğraşan hekimlerin plus hastalığının tanısına ve bu tanıda fikir birliğine yönelik olarak teknolojiyi kullanma istekleri son on yılda belirgin biçimde artmıştır. Bu derlemede PR ve plus hastalığının tanı ve tedaviyi yönlendirmedeki önemi ve bu konuda standardizasyonu sağlamak için yapılan yapılan çalışmalarla ilgili bilgi verilmesi amaçlanmıştır

🔖

Cite This Article

YUMUŞAK, M. E., MUTLU, F. M., SARICA, Ü., OĞUREL, R. (2015). Retinopathy of Prematurity, Diagnosis and Standardization of the Evaluation. Retina-Vitreus, Cilt: 23 - Sayı: 2, 179–185. https://ajindex.com/articles/307889

References (10)

  1. Patz A. Oxygen studies in retrolental fibroplasias: IV: Clinical and ex- perimental observations. Am J Ophthalmol 1954;38:291-308. Ashton N. Oxygen and the retinal blood vessels. Trans OphthalmolSoc UK 1980;100:359-62. No authors listed. An international classification of retinopathy of pre- maturity. ArchOphthalmol 1984;102:1130-4. 4. Davitt BV, Wallace DK. Plus disease. Surv Ophthalmol 2009;54:663-70.
  2. Kretzer FL, Hittner HM. Retinopathy of prematurity: Clinical implica- tions of retinal development. ArchDis Child 1988;63:1151-67. Smith LE. Pathogenesis of retinopathy of prematurity. GrowthHorm IGF Res 2004;14:S140-4. Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neona- tol 2003;8:469-73. 8. Dorrell MI, Aguilar E, Friedlander M. Retinal vascular development is mediated by endothelial filopodia, a preexisting strocytic templateand specific R-cadherin adhesion. Invest Ophthalmol Vis Sci.2002;43:3500-10.
  3. Weidemann A, Krohne TU, Aguilar E, et al. Astrocyte hypoxic respon- se is essential for pathological but not developmental angiogenesis of the retina. Glia 2010;58:1177-85.
  4. McColm JR, Geisen P, Hartnett ME. VEGF isoform sand the irexpression after a single episode of hypoxia or repeated fluctuations between hypero- xia and hypoxia: relevance to clinical ROP Mol Vis. 2004;21:512-20.
  5. Chan-Ling T, McLeod DS, Hughes S, et al. Astrocyte-endothelial cell relationships during human retinal vascular development. Invest Oph- thalmol Vis Sci 2004;45:2020-32.
  6. Smith LE, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Scien- ce.1997;276:1706-9.
  7. Seghezzi G, Patel S, Ren CJ, et al. Fibroblast growthfactor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism cont- ributing to angiogenesis. J Cell Biol 1998;141:1659-73.
  8. Wilkinson-Berka JL, Babic S, De Gooyer T, et al. Inhibition of plate- let-derived growth factor promote spericyte loss and angiogenesis in ischemic retinopathy. Am J Pathol 2004;164:1263-73.
  9. Gille J, Khalik M, König V, et al. Hepatocyte growth factor/ scatter fac- tor (HGF/SF) induces vascular permeability factor (VPF/VEGF) exp- ression by cultured keratinocytes. J Invest Dermatol 1998;111:1160-5.
  10. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promote saccumulation of ascites fluid. Scien- ce 1983;219:983-5. Smith LE. IGF-1 and retinopathy of prematu